Signaling of Ca2+ release from RyR2 is a critical step in cardiac EC-coupling. To gain insight into regulatory mechanisms of Ca2+ release channel (RyR2), we introduced CPVT1-associated W4645R mutation (caffeine-binding site) and N771D mutation (FKBP binding site) corresponding with skeletal disease RyR1 mutation in RYR2 gene of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) by CRISPR/Cas9 gene-editing. Simultaneous Ca2+ imaging and electrophysiological measurement in patch clamped hiPSC-CMs showed: (1) there was no significant differences in activation threshold, reversal potential or voltage-dependent activation and inactivation of Ca2+ current in the two mutants as compared to wild type (WT) myocytes. (2) The W4645R mutant was unresponsive to rapid caffeine (5-20mM) applications, but showed 60% higher ICa-gated Ca2+ release as compared to WT myocytes. (3) N771D mutant had similar fractional release, higher CICR gain, but unexpectedly lower diastolic Ca2+ leak compared to WT cells; and (4) β-adrenergic stimulation (500nM isoproterenol) normalized the significantly lower amplitude and frequency of spontaneous cytosolic Ca2+ oscillations in W4645R, but had no differential effect on N771D mutant compared to WT cells. Our data suggests that W4645R mutation abolishes caffeine-triggered release, but increases ICa-gated Ca2+ release possibly related to enhanced Ca2+ sensitivity of RyR2 as shown in [3H]ryanodine binding assay with recombinant W4645R-RyR2. N771D-RyR2 mutation surprisingly did not show any aberrancy in Ca2+ signaling in sharp contrast to the finding with the truncated RyR protein, showing impaired FKBP binding. Supported by NIH grant HL147054.
Read full abstract